Felsőoktatási Intézményi Kiválósági Program (2019)(TUDFO/47138/2019-ITM) Támogató:
ITM
(EFOP-3.6.1.-16-2016-00004) Támogató: EFOP
(GINOP-2.3.2-15-2016-00044)
(GINOP-2.3.4-15-2020-00008)
(21-5) Támogató: ÚNKP
(K 131493) Támogató: NKFIH
(KH 129599) Támogató: NKFIH
Szakterületek:
Kémiai tudományok
Orvos- és egészségtudomány
The protracted global COVID-19 pandemic urges the development of new drugs against
the causative agent SARS-CoV-2. The clinically used glycopeptide antibiotic, teicoplanin,
emerged as a potential antiviral, and its efficacy was improved with lipophilic modifications.
This prompted us to prepare new lipophilic apocarotenoid conjugates of teicoplanin,
its pseudoaglycone and the related ristocetin aglycone. Their antiviral effect was
tested against SARS-CoV-2 in Vero E6 cells, using a cell viability assay and quantitative
PCR of the viral RNA, confirming their micromolar inhibitory activity against viral
replication. Interestingly, two of the parent apocarotenoids, bixin and ?-apo-8'carotenoic
acid, exerted remarkable anti-SARS-CoV-2 activity. Mechanistic studies involved cathepsin
L and B, as well as the main protease 3CLPro, and the results were rationalized by
computational studies. Glycopeptide conjugates show dual inhibitory action, while
apocarotenoids have mostly cathepsin B and L affinity. Since teicoplanin is a marketed
antibiotic and the natural bixin is an approved, cheap and widely used red colorant
food additive, these readily available compounds and their conjugates as potential
antivirals are worthy of further exploration.